Pearl Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• BFF MDI (PT009) · Respiratory/Pulmonology
  BFF MDI is a combination inhaled therapy containing budesonide, formoterol, and glycopyrronium that reduces airway inflammation and improves bronchodilation in chronic obstructive pulmonary disease.
• BGF MDI (PT010) · Respiratory/Pulmonology
  BGF MDI is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation in chronic obstructive pulmonary disease.
• FF MDI · Respiratory/Pulmonology
  FF MDI is a combination inhaled corticosteroid and long-acting beta-2 agonist for maintenance treatment of asthma and COPD.
• FF MDI (PT005) · Respiratory
  FF MDI is a combination inhaled corticosteroid (fluticasone propionate) and long-acting beta-2 agonist (formoterol) metered-dose inhaler for maintenance treatment of asthma and COPD.
• GFF MDI · Respiratory / Pulmonology
  GFF MDI is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in obstructive airway diseases.
• GFF MDI (PT 003) · Respiratory / Pulmonology
  GFF MDI is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via metered-dose inhaler for maintenance treatment of asthma and COPD.
• GP MDI · Respiratory/Pulmonology
  GP MDI is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via metered-dose inhaler for maintenance treatment of asthma and COPD.
• GP MDI (PT001) · Respiratory/Pulmonology
  PT001 is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via metered-dose inhaler for maintenance treatment of asthma and COPD.
• Symbicort Turbohaler · Respiratory
  Symbicort Turbohaler is a combination of budesonide and formoterol, a corticosteroid and a long-acting beta2-adrenergic receptor agonist, respectively, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).
• Symbicort® Turbohaler® Inhalation Powder · Respiratory
  Symbicort is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).

Phase 2 pipeline

• AZD 2115, Dose 2
• AZD2115 Dose 1
  AZD2115 is an investigational drug with an undisclosed mechanism of action.
• BD MDI 160 µg · Respiratory
  BD MDI 160 µg is a bronchodilator that works by relaxing the muscles in the airways to improve breathing in people with asthma or COPD.
• BD MDI 40 µg · Respiratory
  BD MDI 40 µg is a bronchodilator that works by relaxing the muscles in the airways to improve breathing in people with asthma or COPD.
• BD MDI 80 µg · Respiratory/Pulmonology
  BD MDI 80 µg is a budesonide/formoterol combination inhaler that reduces airway inflammation and improves bronchodilation for respiratory disease management.
• Glycopyrronium MDI · Respiratory
  Anticholinergic
• Glycopyrronium MDI 14.4 micrograms
• Glycopyrronium MDI 28.8 micrograms
• Glycopyrronium MDI 7.2 micrograms · Respiratory
  Glycopyrronium is an anticholinergic that works by blocking the action of acetylcholine at muscarinic receptors, leading to bronchodilation.
• Ipratropium Bromide HFA Inhalation Aerosol · Respiratory
  Anticholinergic agent that inhibits muscarinic acetylcholine receptors
• PT001
• PT001 MDI
• PT003
• PT003 MDI
• PT005
• PT005 MDI

Phase 1 pipeline

• PT009
• PT010
• Tiotropium Handihaler

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Pearl Therapeutics, Inc. portfolio CI brief
• Pearl Therapeutics, Inc. pipeline updates RSS